Targeted therapies for cancer
AssigneesThe Translational Genomics Research Institute, Mayo Foundation for Medical Education and Research
InventorsMitesh Jivraj Borad, David Craig, John Carpten
Life of this patent
Estimating the term…
Abstract
Methods of selecting a chemotherapy regimen for treatment of cancer in a patient are disclosed. A patient genetic sample from a bilary cancer such as cholangiocarcinoma is analyzed for a mutation in ERRFI1 and a chemotherapeutic agent is selected as a result of the analysis. If a mutation in ERRFI1 is present, treatment with an inhibitor of Epidermal Growth Factor Receptor (EGFR) is shown to have inhibitory effects on tumor growth. In this manner, the chemotherapy regimen is targeted to a given mutation in a patient's cancer.
Claims12
A method of treating biliary tract cancer, comprising the steps of:
- analyzing a patient tumor sample for a mutation in ERRFI1 wherein said mutation in ERRFI1 comprises E384X;
- and treating said patient with an inhibitor of Epidermal Growth Factor Receptor (EGFR) if said mutation is present.
A method of inhibiting biliary tract cancer cell growth, comprising contacting a biliary tract cancer cell containing a mutation in ERRFI1 with an Epidermal Growth Factor Receptor (EGFR) inhibitor, wherein said mutation in ERRFI1 comprises E384X.
Dependencies are inferred from the claim text.